Attention-deficit/hyperactivity disorder and lifetime cannabis use: genetic overlap and causality

ADHD Group of the Psychiatric Genomics Consortium, International Cannabis Consortium

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is a severely impairing neurodevelopmental disorder with a prevalence of 5% in children and adolescents and of 2.5% in adults. Comorbid conditions in ADHD play a key role in symptom progression, disorder course and outcome. ADHD is associated with a significantly increased risk for substance use, abuse and dependence. ADHD and cannabis use are partly determined by genetic factors; the heritability of ADHD is estimated at 70–80% and of cannabis use initiation at 40–48%. In this study, we used summary statistics from the largest available meta-analyses of genome-wide association studies (GWAS) of ADHD (n = 53,293) and lifetime cannabis use (n = 32,330) to gain insights into the genetic overlap and causal relationship of these two traits. We estimated their genetic correlation to be r 2 = 0.29 (P = 1.63 × 10 −5 ) and identified four new genome-wide significant loci in a cross-trait analysis: two in a single variant association analysis (rs145108385, P = 3.30 × 10 −8 and rs4259397, P = 4.52 × 10 −8 ) and two in a gene-based association analysis (WDPCP, P = 9.67 × 10 −7 and ZNF251, P = 1.62 × 10 −6 ). Using a two-sample Mendelian randomization approach we found support that ADHD is causal for lifetime cannabis use, with an odds ratio of 7.9 for cannabis use in individuals with ADHD in comparison to individuals without ADHD (95% CI (3.72, 15.51), P = 5.88 × 10 −5 ). These results substantiate the temporal relationship between ADHD and future cannabis use and reinforce the need to consider substance misuse in the context of ADHD in clinical interventions.

Original languageEnglish
Pages (from-to)1-11
Number of pages11
JournalMolecular Psychiatry
DOIs
Publication statusE-pub ahead of print - 4 Jan 2019

Fingerprint

Cannabis
Attention Deficit Disorder with Hyperactivity
Causality
Substance-Related Disorders
Genome-Wide Association Study
Random Allocation
Meta-Analysis
Odds Ratio
Genome

Cite this

ADHD Group of the Psychiatric Genomics Consortium, International Cannabis Consortium. / Attention-deficit/hyperactivity disorder and lifetime cannabis use : genetic overlap and causality. In: Molecular Psychiatry. 2019 ; pp. 1-11.
@article{2af5eaa570f4422298b09ae6e0e7c9c9,
title = "Attention-deficit/hyperactivity disorder and lifetime cannabis use: genetic overlap and causality",
abstract = "Attention-deficit/hyperactivity disorder (ADHD) is a severely impairing neurodevelopmental disorder with a prevalence of 5{\%} in children and adolescents and of 2.5{\%} in adults. Comorbid conditions in ADHD play a key role in symptom progression, disorder course and outcome. ADHD is associated with a significantly increased risk for substance use, abuse and dependence. ADHD and cannabis use are partly determined by genetic factors; the heritability of ADHD is estimated at 70–80{\%} and of cannabis use initiation at 40–48{\%}. In this study, we used summary statistics from the largest available meta-analyses of genome-wide association studies (GWAS) of ADHD (n = 53,293) and lifetime cannabis use (n = 32,330) to gain insights into the genetic overlap and causal relationship of these two traits. We estimated their genetic correlation to be r 2 = 0.29 (P = 1.63 × 10 −5 ) and identified four new genome-wide significant loci in a cross-trait analysis: two in a single variant association analysis (rs145108385, P = 3.30 × 10 −8 and rs4259397, P = 4.52 × 10 −8 ) and two in a gene-based association analysis (WDPCP, P = 9.67 × 10 −7 and ZNF251, P = 1.62 × 10 −6 ). Using a two-sample Mendelian randomization approach we found support that ADHD is causal for lifetime cannabis use, with an odds ratio of 7.9 for cannabis use in individuals with ADHD in comparison to individuals without ADHD (95{\%} CI (3.72, 15.51), P = 5.88 × 10 −5 ). These results substantiate the temporal relationship between ADHD and future cannabis use and reinforce the need to consider substance misuse in the context of ADHD in clinical interventions.",
author = "{Soler Artigas}, Mar{\'i}a and Cristina S{\'a}nchez-Mora and Paula Rovira and Vanesa Richarte and Iris Garcia-Mart{\'i}nez and Mireia Pagerols and Ditte Demontis and Sven Stringer and Vink, {Jacqueline M.} and B{\o}rglum, {Anders D.} and Neale, {Benjamin M.} and Barbara Franke and Faraone, {Stephen V.} and Miguel Casas and Ramos-Quiroga, {Josep Antoni} and Marta Ribas{\'e}s and {ADHD Group of the Psychiatric Genomics Consortium, International Cannabis Consortium}",
year = "2019",
month = "1",
day = "4",
doi = "10.1038/s41380-018-0339-3",
language = "English",
pages = "1--11",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",

}

ADHD Group of the Psychiatric Genomics Consortium, International Cannabis Consortium 2019, 'Attention-deficit/hyperactivity disorder and lifetime cannabis use: genetic overlap and causality' Molecular Psychiatry, pp. 1-11. https://doi.org/10.1038/s41380-018-0339-3

Attention-deficit/hyperactivity disorder and lifetime cannabis use : genetic overlap and causality. / ADHD Group of the Psychiatric Genomics Consortium, International Cannabis Consortium.

In: Molecular Psychiatry, 04.01.2019, p. 1-11.

Research output: Contribution to JournalArticleAcademicpeer-review

TY - JOUR

T1 - Attention-deficit/hyperactivity disorder and lifetime cannabis use

T2 - genetic overlap and causality

AU - Soler Artigas, María

AU - Sánchez-Mora, Cristina

AU - Rovira, Paula

AU - Richarte, Vanesa

AU - Garcia-Martínez, Iris

AU - Pagerols, Mireia

AU - Demontis, Ditte

AU - Stringer, Sven

AU - Vink, Jacqueline M.

AU - Børglum, Anders D.

AU - Neale, Benjamin M.

AU - Franke, Barbara

AU - Faraone, Stephen V.

AU - Casas, Miguel

AU - Ramos-Quiroga, Josep Antoni

AU - Ribasés, Marta

AU - ADHD Group of the Psychiatric Genomics Consortium, International Cannabis Consortium

PY - 2019/1/4

Y1 - 2019/1/4

N2 - Attention-deficit/hyperactivity disorder (ADHD) is a severely impairing neurodevelopmental disorder with a prevalence of 5% in children and adolescents and of 2.5% in adults. Comorbid conditions in ADHD play a key role in symptom progression, disorder course and outcome. ADHD is associated with a significantly increased risk for substance use, abuse and dependence. ADHD and cannabis use are partly determined by genetic factors; the heritability of ADHD is estimated at 70–80% and of cannabis use initiation at 40–48%. In this study, we used summary statistics from the largest available meta-analyses of genome-wide association studies (GWAS) of ADHD (n = 53,293) and lifetime cannabis use (n = 32,330) to gain insights into the genetic overlap and causal relationship of these two traits. We estimated their genetic correlation to be r 2 = 0.29 (P = 1.63 × 10 −5 ) and identified four new genome-wide significant loci in a cross-trait analysis: two in a single variant association analysis (rs145108385, P = 3.30 × 10 −8 and rs4259397, P = 4.52 × 10 −8 ) and two in a gene-based association analysis (WDPCP, P = 9.67 × 10 −7 and ZNF251, P = 1.62 × 10 −6 ). Using a two-sample Mendelian randomization approach we found support that ADHD is causal for lifetime cannabis use, with an odds ratio of 7.9 for cannabis use in individuals with ADHD in comparison to individuals without ADHD (95% CI (3.72, 15.51), P = 5.88 × 10 −5 ). These results substantiate the temporal relationship between ADHD and future cannabis use and reinforce the need to consider substance misuse in the context of ADHD in clinical interventions.

AB - Attention-deficit/hyperactivity disorder (ADHD) is a severely impairing neurodevelopmental disorder with a prevalence of 5% in children and adolescents and of 2.5% in adults. Comorbid conditions in ADHD play a key role in symptom progression, disorder course and outcome. ADHD is associated with a significantly increased risk for substance use, abuse and dependence. ADHD and cannabis use are partly determined by genetic factors; the heritability of ADHD is estimated at 70–80% and of cannabis use initiation at 40–48%. In this study, we used summary statistics from the largest available meta-analyses of genome-wide association studies (GWAS) of ADHD (n = 53,293) and lifetime cannabis use (n = 32,330) to gain insights into the genetic overlap and causal relationship of these two traits. We estimated their genetic correlation to be r 2 = 0.29 (P = 1.63 × 10 −5 ) and identified four new genome-wide significant loci in a cross-trait analysis: two in a single variant association analysis (rs145108385, P = 3.30 × 10 −8 and rs4259397, P = 4.52 × 10 −8 ) and two in a gene-based association analysis (WDPCP, P = 9.67 × 10 −7 and ZNF251, P = 1.62 × 10 −6 ). Using a two-sample Mendelian randomization approach we found support that ADHD is causal for lifetime cannabis use, with an odds ratio of 7.9 for cannabis use in individuals with ADHD in comparison to individuals without ADHD (95% CI (3.72, 15.51), P = 5.88 × 10 −5 ). These results substantiate the temporal relationship between ADHD and future cannabis use and reinforce the need to consider substance misuse in the context of ADHD in clinical interventions.

UR - http://www.scopus.com/inward/record.url?scp=85059569683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059569683&partnerID=8YFLogxK

U2 - 10.1038/s41380-018-0339-3

DO - 10.1038/s41380-018-0339-3

M3 - Article

SP - 1

EP - 11

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

ER -

ADHD Group of the Psychiatric Genomics Consortium, International Cannabis Consortium. Attention-deficit/hyperactivity disorder and lifetime cannabis use: genetic overlap and causality. Molecular Psychiatry. 2019 Jan 4;1-11. https://doi.org/10.1038/s41380-018-0339-3